RTP Mobile Logo

Saturday, November 23, 2019, Phoenix, Arizona, 12:15 PM – 1:15 PM

Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases

A Satellite Symposium During the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology

Event Details

Location
JW Marriott Desert Ridge
5350 E Marriott Drive
Phoenix, AZ 85054
Hotel Phone: (480) 293-5000

Time
11:45 AM – 12:15 PM — Registration and Lunch Buffet
12:15 PM – 1:15 PM — Educational Meeting

Meeting Room
Grand Sonoran F (Level 1)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Manmeet S Ahluwalia, MD
Professor, Miller Family Endowed Chair
in Neuro-Oncology
Associate Director and Head of Operations
Rose Ella Burkhardt Brain Tumor and
Neuro-Oncology Center
Cleveland Clinic
Professor, Cleveland Clinic Lerner College
of Medicine of Case Western Reserve University
Cleveland, Ohio

Daniel Gomez, MD, MBA
Radiation Oncologist
Director of Thoracic Radiation Oncology
Chief of Radiation Oncology, Manhattan Service
Memorial Sloan Kettering Cancer Center
New York, New York

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


Moderator
Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California


The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

Agenda

Meeting Agenda and Format

Prior to this event, the faculty members and 3 other investigators will be asked to complete a case-based Consensus or Controversy (CoC) survey designed to document their usual approaches to a variety of clinical scenarios and management questions. During the program, the responses to specific CoC questions will be graphically displayed for the audience. Short didactic presentations will also be included to provide a formal review of available data and ongoing trials.

MODULE 1: Prevalence and Clinical Significance of Central Nervous System (CNS) Involvement in Non-Small Cell Lung Cancer (NSCLC); Indications for Various Local Treatment Modalities — Dr Gomez

  • Incidence of brain metastasis in NSCLC in various patient subsets; prognostic significance of CNS involvement in NSCLC
  • Potential biologic rationale for the higher incidence of brain metastasis documented among patients with oncogene-driven NSCLC compared to those without targetable genetic abnormalities
  • Practical implementation of multidisciplinary decision-making in the clinical care of patients with brain metastases
  • Available guideline recommendations regarding the use of stereotactic radiosurgery and other local treatment modalities versus whole brain radiation therapy (WBRT) in patients with NSCLC and brain metastases; patient- and disease-related factors influencing this decision
  • Long-term sequelae associated with WBRT (leukoencephalopathy, brain atrophy, radiation necrosis, et cetera); neuroprotective strategies currently under investigation to reduce the risk of WBRT-associated neurocognitive decline

MODULE 2: Optimal Management of Brain Metastases in Oncogene-Driven NSCLC — Dr Riely

  • Historical data on intracranial response rates with first- and second-generation EGFR tyrosine kinase inhibitors (TKIs)
  • Documented activity of the third-generation EGFR TKI osimertinib in patients with CNS metastases in Phase III clinical trials (AURA3, FLAURA)
  • Optimal initial treatment approach for patients with NSCLC with EGFR tumor mutations and brain metastases; impact of extent of disease and symptomatology on the selection of EGFR TKI versus local or combined modality therapy
  • Available clinical trial data on the CNS permeability of approved and investigational ALK inhibitors; implications for the selection and sequencing of therapy for patients with NSCLC and ALK rearrangements
  • Rationale for the continuation of TKI treatment with the addition of local ablative therapies in patients experiencing oligoprogression within the CNS; ongoing clinical trials (eg, HALT) investigating this approach

MODULE 3: Management of Leptomeningeal Metastases (LM) in NSCLC with a Targetable Tumor Mutation; Role of Immune Checkpoint Inhibition in the Treatment of CNS Disease Stemming from NSCLC — Dr Ahluwalia

  • Leptomeningeal disease as a distinct clinical entity; incidence, prognosis and historical management
  • Available clinical outcomes data from studies assessing EGFR TKIs in patients with LM from NSCLC (eg, BLOOM, AURA LM)
  • Published reports assessing ALK TKIs and other targeted therapies in patients with LM from NSCLC
  • Biologic rationale for, available clinical trial data with and current clinical role of anti-PD-1/PD-L1 antibody therapy for patients with metastatic NSCLC and brain or leptomeningeal metastases
  • Potential of radiation therapy to augment antitumor immune responses; ongoing trials combining immune checkpoint inhibition with radiation therapy to the brain in patients with advanced solid tumors and brain metastases

CE Information

Target Audience
This activity is intended for neuro-oncologists, neurosurgeons, medical oncologists and other neuro-oncology practitioners involved in the treatment of lung cancer and CNS metastases.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Discern the overall incidence of central nervous system (CNS) involvement among patients with non-small cell lung cancer (NSCLC), and discuss how the presence of brain or leptomeningeal metastases affects overall prognosis.
  • Differentiate among local therapy techniques for the management of brain metastases stemming from NSCLC, and determine which of these is most appropriate based on patient- and disease-specific factors (performance status, presence of an activating tumor mutation, number and location of lesions, et cetera).
  • Appraise the relative levels of CNS permeability with various EGFR tyrosine kinase inhibitors (TKIs), and discuss how this affects the efficacy of these agents against NSCLC with an EGFR mutation and brain metastases.
  • Review published research data documenting the safety and efficacy of the third-generation EGFR TKI osimertinib in the treatment of brain and leptomeningeal metastases, and discern how this information should be applied to current patient care.
  • Consider the uniqueness of leptomeningeal metastases as a clinical entity, and recall emerging data with promising diagnostic and therapeutic techniques in this setting.
  • Evaluate the activity of FDA-endorsed ALK inhibitors in patients with ALK-rearranged NSCLC and CNS metastases to optimize the selection and sequencing of targeted treatments.
  • Appreciate available clinical trial data with and recall the rationale for ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with NSCLC and brain metastases, and apply this information to provide appropriate counseling about protocol and nonresearch treatment options.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by an educational grant from AstraZeneca.

Location

JW Marriott Desert Ridge
5350 E Marriott Drive
Phoenix, AZ 85054
Hotel Phone: (480) 293-5000

Meeting Room
Grand Sonoran F (Level 1)

Directions
The JW Marriott Desert Ridge hotel is the host venue for the SNO 2019 Annual Meeting.

 

Registration

This activity is intended for neuro-oncologists, neurosurgeons, medical oncologists and other neuro-oncology practitioners involved in the treatment of lung cancer and CNS metastases.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.